GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camurus AB (OTCPK:CAMRF) » Definitions » Capex-to-Revenue

Camurus AB (Camurus AB) Capex-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Camurus AB Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Camurus AB's Capital Expenditure for the three months ended in Mar. 2024 was $-0.16 Mil. Its Revenue for the three months ended in Mar. 2024 was $37.46 Mil.

Hence, Camurus AB's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.00.


Camurus AB Capex-to-Revenue Historical Data

The historical data trend for Camurus AB's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camurus AB Capex-to-Revenue Chart

Camurus AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.25 0.01 0.01 - 0.01

Camurus AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 - 0.01 -

Competitive Comparison of Camurus AB's Capex-to-Revenue

For the Biotechnology subindustry, Camurus AB's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Camurus AB's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camurus AB's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Camurus AB's Capex-to-Revenue falls into.



Camurus AB Capex-to-Revenue Calculation

Camurus AB's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.987) / 167.373
=0.01

Camurus AB's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.157) / 37.458
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Camurus AB  (OTCPK:CAMRF) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Camurus AB Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Camurus AB's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Camurus AB (Camurus AB) Business Description

Traded in Other Exchanges
Address
Ideon Science Park, Lund, SWE, SE-223 70
Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The company's product pipeline includes CAM2038, CAM2029, CAM2032, and others. The company's geographical revenue includes Europe (of which Sweden), the United States of America, Australia, and Other geographical areas.